0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Arno Therapeutics
Its shares trade under the ticker ARNI. It has been listed since 11 June 2008.
Arno Therapeutics, Inc. is a biopharmaceutical company, which focuses on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs. The company is headquartered in Flemington, New Jersey. The company went IPO on 2008-06-11. The firm's product development pipeline includes Onapristone, AR-42, and AR-12 and analogs. Onapristone is indicated for endometrial, prostate and breast cancer indications. AR-42 is provided for hematological malignancies and solid tumors indications. AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets. Onapristone is a type 1 anti-progestin hormone blocker that has considerable anti-tumor activity in patients with breast cancer. The firm is engaged in developing and commercializing AR-42, which is an oral cancer therapy in early clinical development. AR-42 is a spectrum deacetylase inhibitor of both histone and non-histone proteins, which has potency and activity in solid tumors and hematological malignancies. AR-12 is an orally available cancer treatment.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 11 Jun 2008
- Employees
- 7
Leadership
Pay as last reported
- Dr. Arie BelldegrunChairman of the Board, since 2008
- Dr. Alexander ZukiwskiChief Executive Officer, Chief Medical Officer, Vice President, Director, since 2011$2.2m
- Mr. Stefan ProniukChief Development Officer, since 2014$681,464
- Mr. David TanenSecretary, Director, since 2011
- Mr. Jay MoorinDirector
- Dr. William HamiltonIndependent Director
- Mr. Tomer KarivIndependent Director
- Mr. Yacov ReizmanIndependent Director
- Mr. Steven RuchefskyIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Arno Therapeutics Inc has a strong and experienced management team that brings expertise in the biotechnology industry, enabling effective decision-making and strategic planning.
- The company possesses a diverse portfolio of innovative drug candidates with promising potential, which provides growth opportunities and the ability to address various medical conditions.
- Arno Therapeutics Inc has developed strategic partnerships and collaborations with reputable research institutions, enabling access to cutting-edge technology and scientific advancements.
Weaknesses
- The company is heavily reliant on external funding sources, which may result in financial constraints and limitations on the speed of research and development activities.
- Arno Therapeutics Inc has a relatively small market presence compared to larger competitors, which makes it susceptible to market fluctuations and challenges in gaining market share.
- The company's limited resources may hinder its ability to effectively market and commercialize its drug candidates, potentially limiting revenue generation.
Opportunities
- Arno Therapeutics Inc can leverage the growing demand for innovative and targeted treatment options in the biotechnology sector, potentially leading to increased adoption and potential market expansion.
- The company can explore potential collaboration opportunities with pharmaceutical giants or larger biotech companies, allowing access to additional resources, expertise, and distribution networks.
- The advancements in personalized medicine and genomic research present an opportunity for Arno Therapeutics Inc to develop tailored therapies and treatments, addressing specific patient populations.
Threats
- Arno Therapeutics Inc operates in a highly competitive industry, with numerous established companies and new entrants, increasing the risk of market saturation and pricing pressures.
- Regulatory changes and stringent approval processes in the biotech sector can pose challenges and delay the commercialization of Arno Therapeutics Inc's drug candidates.
- Macro-economic factors and global healthcare policies may impact the availability of funding and reimbursement for medical treatments, potentially affecting the company's financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.